437
Participants
Start Date
December 15, 2017
Primary Completion Date
March 31, 2021
Study Completion Date
June 30, 2022
(vic-)trastuzumab duocarmazine
Intravenous SYD985, Q3W
Physician's choice
See drug label
Istituto Nazionale dei Tumori Regina Elena, Roma
Azienda Ospedaliera Sant'Andrea, Roma
Institut Jules Bordet, Brussels
Cliniques Universitaires Saint-Luc, Brussels
University Hospital Antwerp, Edegem
UZ Leuven - campus Gasthuisberg, Leuven
Hospital General Universitario de Alicante, Alicante
Sealand University Hospital, Næstved
Sønderborg sygehus, Sønderborg
Hospital Universitari Vall d'Hebron Vall d' Hebron Institute of Oncology (VHIO), Barcelona
Hospital Clinic de Barcelona, Barcelona
AZ Groeninge, Kortrijk
Institut Catala D'oncologia, Barcelona
UZ Gent, Ghent
Magee-Womens Hospital of UPMS, Pittsburgh
IRCCS Ospedale San Raffaele, Milan
Fondazione IRCCS Istituto Nazionale dei Tumori, Milan
Istituto Europeo di Oncologia, Milan
Ospedale San Gerardo-Asst Monza, Monza
Centre Georges francois leclerc, Dijon
University of Maryland Greenebaum Cancer Center, Baltimore
Greater Baltimore Medical Center, Baltimore
Hospital Arnau de Vilanova, Lleida
Virginia Cancer Specialists, PC, Fairfax
Virginia Oncology Associates, Norfolk
Hospital General Universitario Gregorio Marañón, Madrid
IOB del Hospital Ruber Internacional, Madrid
Hospital HM Universitario Sanchinarro, Madrid
FirstHealth Outpatient Cancer Center, Pinehurst
Woodlands Medical Specialists, Pensacola
Institut Bergonie, Bordeaux
Istituto Oncologico Veneto Irccs, Padua
Southern Cancer Center, Mobile
Policlinico S.Orsola-Malpighi, Bologna
University Hospital of Modena, Modena
Toledo Clinic Cancer Center, Toledo
Hopital Prive du Confluent, Nantes
Hospital Clinico Universitario de Valencia, Valencia
Henry Ford Hospital, Detroit
Institut de Cancerologie de l'ouest, Angers
Hospital Universitario Miguel Servet, Zaragoza
Azienda Ospedaliero - Universitaria Careggi, Florence
CHR Metz-Thionville, Metz
Oscar Lambret, Lille
Nuovo Ospedale Santo Stefano, Prato
Rush University Medical Center, Chicago
Saint Luke's Hospital of Kansas City, Kansas City
Centre Paul Strauss, Strasbourg
Cancer Center of Kansas, Wichita
Centre Hospitalier Lyon Sud, Pierre-Bénite
IRCCS Istituto Oncologico, Bari
Casa Sollievo Della Sofferenza, San Giovanni Rotondo
Texas Oncology PA (Texas Oncology-Dallas Presbyterian Hospital), Dallas
Texas Oncology- Baylor Charles A. Sammor, Dallas
Hopital Saint Louis, Paris
Texas Oncology-Tyler, Tyler
Centre Henri Becquere, Rouen
Texas Oncology - Denton South, Denton
Texas Oncology-Memorial City, Houston
Texas Oncology-San Antonio Northeast, San Antonio
Akademiska Hospital, Uppsala
Gävle Sjukhus Onkologkliniken, Gävle
Arizona Clinical Research Center, Tucson
Centre Hospitalier Lyon Sud, Corbeil-Essonnes
Moores UCSD Cancer Center, San Diego
Azienda Ospedaliera Garibaldi- Nesima, Catania
Northwest Cancer Specialists, Portland
National University Cancer Institute, Singapore
National Cancer Centre Singapore, Singapore
Baylor College of Medicine, Houston
CHU Liege, Liège
Cross Cancer Institute, Edmonton
BC Cancer Agency Centre for the Southern Interior, Kelowna
McGill University Health Centre, Montreal
The Ottawa Hospital Cancer Center, Ottawa
Odense University Hospital, Odense
CH Fleyrait, Bourg-en-Bresse
Radboud University Medical Center, Nijmegen
VU Medical Center, Amsterdam
University Medical Center Groningen, Groningen
Hospital Quironsalud, Barcelona
Sahlgrenska University Hospital, Gothenburg
Karolina University Hospital, Stockholm
The Clatterbridge Cancer Centre NHS Foundation Trust, Bebington
Velindre Cancer Centre VCC, Cardiff
Beatson West of Scotland Cancer Centre, Glasgow
The Royal Marsden NHS Foundation Trust, London
SCRI UK, London
The Christie NHS Foundation, Manchester
Oxford University NHS hospital, Oxford
Lead Sponsor
Byondis B.V.
INDUSTRY